Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kenji Takanashi
Institution:
Chugai Pharmaceutical Co., Ltd. (Japan)
Observed institutions:
Chiba University,
Chugai Pharmaceutical Co., Ltd. (Japan)
OpenAlex ID:
A5111609321
CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates
2000
·
Kenji Takanashi
, Hitoshi Tainaka
, et al.
·
Pharmacogenetics
·
282
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
2014
·
Tatsushi Kodama
, Masami Hasegawa
, et al.
·
Cancer Chemotherapy and Pharmacology
·
249
Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
2011
·
Kazutomo Kinoshita
, Kohsuke Asoh
, et al.
·
Bioorganic & Medicinal Chemistry
·
180
9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors
2011
·
Kazutomo Kinoshita
, Takamitsu Kobayashi
, et al.
·
Journal of Medicinal Chemistry
·
90
Fluorine Scanning by Nonselective Fluorination: Enhancing Raf/MEK Inhibition while Keeping Physicochemical Properties
2013
·
Ikumi Hyohdoh
, Noriyuki Furuichi
, et al.
·
ACS Medicinal Chemistry Letters
·
45
Prediction of Drug-Drug Interactions based on Time-Dependent Inhibition from High Throughput Screening of Cytochrome P450 3A4 Inhibition
2009
·
Nobuo Sekiguchi
, Atsuko Higashida
, et al.
·
Drug Metabolism and Pharmacokinetics
·
44
Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure-Activity Relationships of Its Derivatives
2008
·
Kazutaka Tachibana
, Ikuhiro Imaoka
, et al.
·
Chemical and Pharmaceutical Bulletin
·
27
PDF
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning
2014
·
Toshihiro Aoki
, Ikumi Hyohdoh
, et al.
·
ACS Medicinal Chemistry Letters
·
26
Metabolites of alectinib in human: their identification and pharmacological activity
2017
·
Mika Sato-Nakai
, Kosuke Kawashima
, et al.
·
Heliyon
·
24
PDF
In vitrometabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes
2017
·
Toshito Nakagawa
, Stephen Fowler
, et al.
·
Xenobiotica
·
24
The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors
2013
·
Toshihiro Aoki
, Ikumi Hyohdoh
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
24
Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer
2018
·
Hiroshi Tanaka
, Hitoshi Sase
, et al.
·
Molecular Cancer Therapeutics
·
20
Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib
2016
·
Nobuo Sekiguchi
, Shunsuke Nagao
, et al.
·
Xenobiotica
·
13
Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor
2022
·
Toshiya Ito
, Kazutomo Kinoshita
, et al.
·
Journal of Medicinal Chemistry
·
9
In vitro metabolism of alectinib, a novel highly potent alk inhibitor: Contribution of CYP3A enzymes in microsomes and hepatocytes
2017
·
Toshito Nakagawa
, Kenji Takanashi
, et al.
·
Drug Metabolism and Pharmacokinetics
·
5
Abstract 754: Selective ALK inhibitor alectinib (CH5424802/RO5424802) with potent antitumor activity in models of crizotinib resistance, including intracranial metastases
2014
·
Tatsushi Kodama
, Toshiyuki Tsukaguchi
, et al.
·
Cancer Research
·
4
Abstract 2789: Discovery of a novel specific MEK and Raf inhibitor, CH5126766 (RO5126766), hit to lead study of a unique scaffold for kinase inhibitor to a clinical compound
2011
·
Hitoshi Iikura
, Toshihiro Aoki
, et al.
·
Cancer Research
·
1
Table S1 from Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer
2023
·
Hiroshi Tanaka
, Hitoshi Sase
, et al.
Figures S1-5 & Tables S2-5 from Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer
2023
·
Hiroshi Tanaka
, Hitoshi Sase
, et al.
Data from Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer
2023
·
Hiroshi Tanaka
, Hitoshi Sase
, et al.
Table S1 from Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer
2023
·
Hiroshi Tanaka
, Hitoshi Sase
, et al.
Figures S1-5 & Tables S2-5 from Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer
2023
·
Hiroshi Tanaka
, Hitoshi Sase
, et al.
PDF
Abstract 3593: Generation of a potent and selective inhibitor of ALK, CH5424802, showing superior oral bioavailability, PK profile and in vivo efficacy
2011
·
Nobuhiro Oikawa
, Kazutomo Kinoshita
, et al.
·
Cancer Research
Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11): 1555-1561 (2008)]
2009
·
Kazutaka Tachibana
, Ikuhiro Imaoka
, et al.
·
Chemical and Pharmaceutical Bulletin
PDF
Influence of the substitution of Leu359 for lle359 on the catalytic activity of CYP2C9
1998
·
Kenji Takanashi
, Hitoshi Tainaka
, et al.
·
The Japanese Journal of Pharmacology
Show more works
View as search
Works count:
25
Citation count:
1,067
H-index:
13
I10-index:
13
Year
Topic
Type